The Drug That Worked Perfectly and Still Failed

BiopharmaDive described it as a "major setback" that "caught Wall Street analysts and investors by surprise." And for good reason: how does a drug do everything right biologically and still miss the mark clinically?

The Stabilizer Problem

The answer might be hiding in the trial's own design. A majority of patients were already taking a TTR stabilizer (drugs like tafamidis that prevent the protein from misfolding in the first place). When you looked at the subgroup of patients who were not on a stabilizer, eplontersen showed a 29% reduction in cardiovascular death and events, with a hazard ratio of 0.71. That's a meaningful signal.

But in patients already on a stabilizer? Zero additional benefit. Nothing. Nada.

Leerink Partners analyst Andrew Berens offered a blunt interpretation: the result "reignites the debate comparing silencers vs. stabilizers" and "suggests there could be no benefit to a combination approach." He also predicted this would increase "payer push-back on combination therapies."

It's a bit like adding a second lock to a door that's already deadbolted. Technically more secure, but practically redundant. If stabilizers are already preventing the protein from misbehaving, silencing the protein's production may not add much on top.

What This Means for the $5 Billion ATTR Battlefield

The ATTR cardiomyopathy market is one of the hottest spaces in cardiology, with multiple companies fighting for a piece. Pfizer's tafamidis remains the established king of the stabilizer class. BridgeBio's acoramidis, which won FDA approval in 2024, is the most dangerous challenger in that same lane. And Alnylam's vutrisiran (Amvuttra) represents the RNA-silencing competition.

Eplontersen's failure effectively takes AstraZeneca and Ionis out of this race, at least for now. The drug keeps its approval for hereditary ATTR polyneuropathy (the nerve damage indication), but the much larger cardiomyopathy market slips away.

For Alnylam, this is a mixed blessing. One fewer competitor is always nice, but the result also raises uncomfortable questions about whether any silencer can show incremental benefit on top of stabilizers. That's a cloud that could hang over the entire class.

AstraZeneca's Bigger Picture

For AstraZeneca specifically, this stings but doesn't cripple. The company's cardiovascular pipeline extends well beyond ATTR. Its recently approved hypertension drug Baxfendy carries an estimated peak revenue of around $5 billion. An oral PCSK9 inhibitor and a new Lp(a)-targeting therapy are also moving through development.

AstraZeneca grouped CARDIO-TTRansform with several other 2026 readouts representing a combined risk-adjusted peak revenue opportunity of more than $10 billion. Losing one piece of that puzzle hurts, but the company's $80 billion revenue ambition for 2030 still rests primarily on its oncology franchise and broader CVRM (cardiovascular, renal, and metabolic) portfolio.

Expect a contained stock hit, not a meltdown.

The Real Lesson Here

The most fascinating takeaway isn't about one drug or one company. It's about what happens when biology doesn't equal medicine.

Eplontersen crushed TTR levels. It improved biomarkers and imaging. By every mechanistic measure, it worked. But in a population already well-managed on stabilizers, that biological success couldn't clear the highest bar: fewer people dying or ending up in the hospital.

RBC Capital's Luca Issi had previously noted that the trial's timeline was extended because cardiovascular events were tracking below expectations. Translation: modern standard of care is so good that it's getting harder and harder to prove new drugs add something on top.

That's a problem the entire industry is grappling with, not just in ATTR but across cardiovascular medicine. When the baseline keeps improving, the finish line keeps moving. And sometimes, even the drugs that do everything right still can't cross it.

The Virus No One Has a Drug For (and the €700M Bet to Change That)

Ipsen just dropped up to €700 million on a Swiss biotech's antibody that targets a virus most people have never heard of. The catch: it's the only thing in development for a condition that wrecks transplanted kidneys, and the Phase II results are messy enough to make things interesting.